These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 15996703)

  • 1. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
    Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
    Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of small-molecule human immunodeficiency virus type 1 entry inhibitors that target the gp120-binding domain of CD4.
    Yang QE; Stephen AG; Adelsberger JW; Roberts PE; Zhu W; Currens MJ; Feng Y; Crise BJ; Gorelick RJ; Rein AR; Fisher RJ; Shoemaker RH; Sei S
    J Virol; 2005 May; 79(10):6122-33. PubMed ID: 15857997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New anti-HIV agents and targets.
    De Clercq E
    Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polyanionic (i.e., polysulfonate) dendrimers can inhibit the replication of human immunodeficiency virus by interfering with both virus adsorption and later steps (reverse transcriptase/integrase) in the virus replicative cycle.
    Witvrouw M; Fikkert V; Pluymers W; Matthews B; Mardel K; Schols D; Raff J; Debyser Z; De Clercq E; Holan G; Pannecouque C
    Mol Pharmacol; 2000 Nov; 58(5):1100-8. PubMed ID: 11040059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions.
    Caporuscio F; Tafi A; González E; Manetti F; Esté JA; Botta M
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6087-91. PubMed ID: 19783140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
    Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
    Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific CD4 down-modulating compounds with potent anti-HIV activity.
    Vermeire K; Schols D
    J Leukoc Biol; 2003 Nov; 74(5):667-75. PubMed ID: 12960237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A peptidomimetic HIV-entry inhibitor directed against the CD4 binding site of the viral glycoprotein gp120.
    Neffe AT; Meyer B
    Angew Chem Int Ed Engl; 2004 May; 43(22):2937-40. PubMed ID: 15170309
    [No Abstract]   [Full Text] [Related]  

  • 9. How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors.
    Hamza A; Zhan CG
    J Phys Chem B; 2006 Feb; 110(6):2910-7. PubMed ID: 16471901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble gC1q-R/p33, a cell protein that binds to the globular "heads" of C1q, effectively inhibits the growth of HIV-1 strains in cell cultures.
    Szabó J; Cervenák L; Tóth FD; Prohászka Z; Horváth L; Kerekes K; Beck Z; Bácsi A; Erdei A; Peerschke EI; Füst G; Ghebrehiwet B
    Clin Immunol; 2001 May; 99(2):222-31. PubMed ID: 11318594
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.
    Biorn AC; Cocklin S; Madani N; Si Z; Ivanovic T; Samanen J; Van Ryk DI; Pantophlet R; Burton DR; Freire E; Sodroski J; Chaiken IM
    Biochemistry; 2004 Feb; 43(7):1928-38. PubMed ID: 14967033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel, negatively charged, human serum albumins display potent and selective in vitro anti-human immunodeficiency virus type 1 activity.
    Jansen RW; Schols D; Pauwels R; De Clercq E; Meijer DK
    Mol Pharmacol; 1993 Nov; 44(5):1003-7. PubMed ID: 7902528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.
    Schön A; Madani N; Klein JC; Hubicki A; Ng D; Yang X; Smith AB; Sodroski J; Freire E
    Biochemistry; 2006 Sep; 45(36):10973-80. PubMed ID: 16953583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 mimics targeting the mechanism of HIV entry.
    Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H
    Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evidence by peptide mapping that the region CD4(81-92) is involved in gp120/CD4 interaction leading to HIV infection and HIV-induced syncytium formation.
    Kalyanaraman VS; Rausch DM; Osborne J; Padgett M; Hwang KM; Lifson JD; Eiden LE
    J Immunol; 1990 Dec; 145(12):4072-8. PubMed ID: 1701782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical role of Arg59 in the high-affinity gp120-binding region of CD4 for human immunodeficiency virus type 1 infection.
    Fontenot D; Jones JK; Hossain MM; Nehete PN; Vela EM; Dwyer VA; Jagannadha Sastry K
    Virology; 2007 Jun; 363(1):69-78. PubMed ID: 17320923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches.
    De Clercq E
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1800-22. PubMed ID: 15183346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of CD4 in HIV binding and entry.
    Sattentau QJ; Moore JP
    Philos Trans R Soc Lond B Biol Sci; 1993 Oct; 342(1299):59-66. PubMed ID: 7904348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic CD4 exocyclics inhibit binding of human immunodeficiency virus type 1 envelope to CD4 and virus replication in T lymphocytes.
    Zhang X; Gaubin M; Briant L; Srikantan V; Murali R; Saragovi U; Weiner D; Devaux C; Autiero M; Piatier-Tonneau D; Greene MI
    Nat Biotechnol; 1997 Feb; 15(2):150-4. PubMed ID: 9035140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.